Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights Newswire.ca - Thu May 9, 3:01PM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 FinancialNewsMedia - Thu May 9, 11:15AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
ZLAB : 20.08 (-4.43%)
NTBL : 1.2500 (-15.54%)
CRDF : 3.39 (+0.30%)
JNJ : 149.91 (+0.04%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer FinancialNewsMedia - Thu May 9, 9:56AM CDT

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study   Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Newswire.ca - Thu May 9, 9:22AM CDT

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.1700 (-5.65%)
CADL : 9.32 (-6.52%)
AZN : 77.18 (-0.55%)
HALO : 43.15 (-1.57%)
JANX : 48.92 (-5.81%)
ONC.TO : 1.59 (-5.92%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer Newswire.ca - Thu May 9, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference Newswire.ca - Wed May 8, 6:00AM CDT

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

RY : 103.21 (+0.12%)
RY.TO : 141.08 (+0.09%)
ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Newswire.ca - Fri May 3, 11:15AM CDT

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

ONCY : 1.1700 (-5.65%)
CELC : 16.83 (-3.00%)
OLMA : 9.32 (-5.28%)
BIO : 282.00 (+1.69%)
AZN : 77.18 (-0.55%)
ONC.TO : 1.59 (-5.92%)
Biotech's Developments in Race Against Rising Cancer Rates Revealed BayStreet.ca - Fri May 3, 10:46AM CDT

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
CELC : 16.83 (-3.00%)
OLMA : 9.32 (-5.28%)
BIO : 282.00 (+1.69%)
AZN : 77.18 (-0.55%)
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response Newswire.ca - Tue Apr 30, 9:30AM CDT

/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...

ONCY : 1.1700 (-5.65%)
ICCM : 1.1400 (-2.56%)
ATOS : 1.4900 (-11.83%)
ARVN : 31.44 (-1.60%)
PFE : 28.01 (-0.60%)
ONC.TO : 1.59 (-5.92%)
Biotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming Rate BayStreet.ca - Tue Apr 30, 9:04AM CDT

USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
ICCM : 1.1400 (-2.56%)
ATOS : 1.4900 (-11.83%)
ARVN : 31.44 (-1.60%)
PFE : 28.01 (-0.60%)

Barchart Exclusives

3 Dividend Kings That Cut (Or Will Cut) Their Dividends Barchart - 24 minutes ago
Dividend aristocracy isn't always a sure thing. Here are 3 companies that have been or will be booted from the coveted king's list. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot